domperidone/naproxen / Generic mfg. - LARVOL DELTA

A simple eco-friendly spectrofluorimetric resolution approach for the simultaneous determination of Naproxen and Domperidone in pharmaceutical formulation and human plasma; assessment of method greenness. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "In compliance with the ICH requirements, the optimized method was validated and was successfully utilized for the determination of both drugs in their pharmaceutical formulation and human plasma. Finally, the greenness of the proposed method was assessed using different assessment tools."

Journal

HPLC-Fluorescence Detection Method for Concurrent Estimation of Domperidone and Naproxen. Validation and Eco-Friendliness Appraisal Studies. (PubMed, J Fluoresc) - "The validated method was successfully applied to the analysis of DOM and NAP in their laboratory prepared tablets resembling the commercial dosage form, and assay results were favorably compared with a published reference HPLC method. The method's greenness was assessed using the Analytical Eco-Scale and the novel Analytical Greenness metric (AGREE)."

Journal

Clinical Characteristics and Management of Headache: A Real-Life Prospective, Observational Study From a Tertiary Care Center in Eastern India. (PubMed, Cureus) - "In our study, migraine was the most common etiology of headache. Headache was more common in females than males, and primary headache was more common than secondary headache. Sodium valproate was the commonly used prophylaxis in migraine."

Clinical • Journal • Observational data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Immunology • Migraine • Musculoskeletal Pain • Otorhinolaryngology • Pain • Respiratory Diseases • Sinusitis • Subarachnoid Hemorrhage • Thrombosis

TrkA inhibitor disappoints in knee osteoarthritis trial (Medicine Matters Rheumatology) - P2, N=127; NCT02611466; Sponsor: Genzyme; "...Tuhina Neogi...suggest that '[s]tudy population differences between the trials might have contributed to better signal detection over placebo in the trial of GZ389988A.' They explain that the GZ389988A trial excluded patients with high neuropathic-like pain scores, and included 'only participants with minimal pain in the contralateral knee.'"

Media quote • P2 data